GUILFORD, CT (Feb. 19, 2021) – Detect, a 4Catalyzer medical technology company, today announced that Michael Mina, M.D., Ph.D., will serve as a Medical Advisor to the company. Dr. Mina joins Detect as the company is pursuing a point of care FDA Emergency Use Authorization for its accurate, fast, and easy-to-use molecular Covid-19 test. Detect also is rapidly completing the development of its at-home test for anyone who wants to test themselves and their loved ones in the safety and comfort of their own home.
“Dr. Mina joins us at a critical time as we look to get our Detect Covid-19 Test out to those who need it,” said Jonathan M. Rothberg, Ph.D., Founder and Chairman of Detect. “He is an expert on SARS-CoV-2, operating at the forefront of the Covid-19 response since the virus emerged and advocating for expansion of mass testing in the U.S. His work includes advising governments and institutions in the U.S. and internationally. Since Dr. Mina is best known for his advocacy of rapid antigen testing, the fact that he has joined a molecular testing company is a testament to his belief in the impact of our product and in the talented people at Detect.”
As a Medical Advisor, Dr. Mina will consult with the Detect executive team and scientists on R&D plans and clinical strategy with the goal of helping them launch the point of care test that is pending at FDA now, and complete the development of a home version. Longer term, he will help Detect build out their platform to take on other communicable diseases, starting with the addition of influenza to the Covid-19 platform.
“Since the start of the pandemic, I have helped develop the scientific foundations that show the impact that new approaches to testing can have to curb spread and get us back to some level of normalcy – particularly as we await vaccines across the globe. The clear conclusions from that work, which is now out in the peer-reviewed literature, led me to urge government regulators, policymakers, industry, and the public health community to unite around fast, simple, accessible, and accurate Covid-19 testing to help get us out of this pandemic,” said Dr. Mina. “For me, Detect stands out because of the scientific approach, vision, and focus on designing a high-performing molecular test that can quickly be scaled to fight Covid-19 and future pandemics. Unlike many other tests, it was designed with cost and manufacturing simplicity in mind. I believe the Detect Covid-19 Test will play an important role in helping us overcome this virus.”
“On a more personal note, this is an opportunity for me to help translate my expertise in public health epidemiology, laboratory sciences, and medicine into real-world tools to help people. Too often as academics we find ourselves publishing research papers and then hoping that someone or some company will pick up those papers and build something to better society with them. With Detect, I have an opportunity to actually help steer a stellar company full of exceptional scientists and leaders in a direction that, I think, will make the greatest good for the greatest number of people. If Covid-19 has taught me anything about myself, it is that I don’t want to just do the science and advocate for change from the sidelines. I want to help make change happen and directly enhance public health, and this is an opportunity for me to do this. Advising Detect gives me an opportunity to translate my science and advocacy into action,” said Dr. Mina.
Dr. Mina is an expert in viral testing protocols and a vocal advocate for a national testing strategy. He is an assistant professor of epidemiology at the Harvard T.H. Chan School of Public Health and a core member of the School’s Center for Communicable Disease Dynamics (CCDD). He also is an assistant professor in immunology and infectious diseases at the Harvard T.H. Chan School and associate medical director in clinical microbiology (molecular diagnostics) in the Department of Pathology at Brigham and Women’s Hospital, Harvard Medical School. He earned his M.D. and Ph.D. degrees from Emory University, and post-doctoral work in infectious diseases at Princeton University and Harvard Medical School.